APEIRON Biologics and Evotec have both received the first milestone payment from Sanofi under a 3-party alliance signed in August 2015. The milestone payment of €3 million will be split equally between the two biotech companies. The success payment was triggered when the partners successfully advanced an undisclosed, novel, immuno-oncology small molecule into late-stage pre-clinical development.    Dr Hans Loibner, chief executive officer of APEIRON Biologics, said, “We are delighted by ...